前收市價 | 10.50 |
開市 | 10.50 |
買盤 | 8.40 |
賣出價 | 9.70 |
拍板 | 82.50 |
到期日 | 2024-06-21 |
今日波幅 | 10.50 - 10.50 |
合同範圍 | 無 |
成交量 | |
未平倉合約 | 24 |
Moderna Inc (NASDAQ:MRNA) has reportedly achieved a significant victory at the European Patent Office (EPO) in its ongoing legal battle with Pfizer Inc (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) over the Covid-19 vaccine. The EPO’s Opposition Division upheld the validity of one of Moderna’s crucial patents, boosting the mRNA vaccine maker’s efforts to reclaim pandemic profits from its competitors, the Financial Times reports. Although Pfizer has nine months to appeal the decision, the EPO’s writte
BioNTech SE (NASDAQ:BNTX) Q1 2024 Earnings Call Transcript May 6, 2024 BioNTech SE isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Welcome to BioNTech’s First Quarter 2024 Earnings Call. I would like to hand the call over to Dr. Victoria […]
BioNTech stock lifted a fraction Monday after Covid vaccine sales dropped again in the first quarter, amid wide losses.